ERBB2 and breast carcinoma: Treatment with HVH-2930 was observed to alleviate HSF1 phosphorylation, thereby preventing nuclear accumulation and HSP70 upregulation in HER2-positive breast cancer cells, without inducing HSF1 transcriptional activity.